|Conditional recommendation based on low-quality evidence; may consider not following a treat-to-target strategy in patients in whom higher frequency and/or severity of adverse events, higher cost of therapy, or higher patient burden of medications with tighter control are a concern.| |
|In patients with active PsA with psoriatic spondylitis/axial disease despite treatment with NSAIDs,â€¡| |
|2. Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 46)|Very low|